Saturday 17 October 2026
Export ARQT’s income statement to Excel — free account
Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
28.82
0.28
−0.96%
Follow ARQT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
119.18 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
7.38 | 7.33 | 9.82 | 7.57 | |
P/FCF ratio |
142.16 | 269.53 | 0.00 | 0.00 | |
P/Operating CF |
270.77 | 1,361.25 | 141.11 | (1,371.55) | |
P/B ratio |
15.52 | 16.07 | 19.50 | 15.22 | |
Price to Tangible BV |
16.54 | 17.38 | 21.15 | 16.86 | |
EV/Sales |
7.10 | 7.06 | 9.53 | 7.31 | |
EV/EBITDA |
92.59 | 724.90 | 0.00 | 0.00 | |
EV/Operating CF |
83.76 | 108.65 | (636.90) | (71.34) | |
EV/FCF |
136.76 | 259.37 | (168.11) | (48.15) | |
Quick Ratio |
2.46 | 2.26 | 2.83 | 3.07 | |
Current Ratio |
2.92 | 2.68 | 3.17 | 3.50 | |
Net Debt/EBITDA |
(7.75) | 13.19 | (5.92) | (9.71) | |
Debt/Assets |
22.29% | 23.79% | 25.17% | 29.25% | |
Debt/Equity |
0.49 | 0.58 | 0.58 | 0.69 | |
Asset Turnover |
1.10 | 1.03 | 0.96 | 0.79 | |
Operating CF/Net income |
0.84 | (0.20) | 1.51 | (0.24) | |
Capex/Depreciation |
(0.46) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
4.82 | (2.08) | 6.13 | 2.78 | |
Research and Development Expense of Revenue |
15.67% | 29.06% | 15.79% | 19.76% | |
Selling, General and Administrative Expense of Revenue |
63.25% | 70.28% | 60.98% | 62.90% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.04 | |
Share Based Compensation of Revenue |
9.83% | 10.14% | 7.77% | 10.12% | |
Graham Net Nets |
0.06 | 0.06 | 0.05 | 0.06 | |
Graham Number |
2.89 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
0.84% | (0.08%) | (0.45%) | (1.91%) | |
Free Cash Flow Yield |
0.70% | 0.37% | (0.58%) | (2.01%) | |
Revenue per Share |
0.99 | 0.81 | 1.02 | 0.78 | |
Operating CF per Share |
0.10 | 0.02 | 0.21 | (0.01) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.10 | 0.02 | 0.21 | (0.01) | |
Cash per Share |
1.83 | 1.73 | 1.74 | 1.50 | |
Shareholders Equity per Share |
1.69 | 1.47 | 1.49 | 1.24 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.69 | 1.47 | 1.49 | 1.24 | |
Free Cash Flow |
12.48 | 2.24 | 26.19 | (1.75) | |
Working Capital |
307.33 | 274.85 | 281.39 | 249.45 | |
Capital Expenditures |
(0.16) | — | 0.00 | 0.00 | |
Net Current Asset Value |
199.71 | 167.70 | 167.74 | 136.32 | |
EV/EBIT |
96.12 | 912.84 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
99.91 | 948.60 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
130.93 | 114.90 | 109.65 | 87.62 | |
Average Payables |
10.84 | 21.41 | 13.37 | 12.56 | |
Average Inventory |
27.60 | 27.00 | 18.58 | 18.22 | |
Average Assets |
420.49 | 402.05 | 390.93 | 404.17 | |
Average Common Equity |
179.78 | 166.15 | 173.51 | 157.36 |
Columns are period end dates